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Abstract A crucial parameter for activation of the anti-tumor
immune response is an adequate antigen availability (AAA)
defined here as the optimal tumor antigen dose and related
antigen processing and MHC-II-restricted presentation neces-
sary to efficiently trigger tumor-specific TH cells. We will
discuss two distinct experimental systems: a) a preventive
anti-tumor vaccination system; b) a therapy-induced anti-
tumor vaccination approach. In the first case tumor cells are
rendered constitutively MHC-II+ by transfecting them with
the MHC-II transcriptional activator CIITA. Here AAA is
generated by the function of tumor’s newly expressed MHC-
II molecules to present tumor-associated antigens to tumor-
specific TH cells. In the second case, AAA is generated by
treating established tumors with neovasculature-targeted
TNFα. In conjuction withMelphalan, targeted TNFα delivery
produces extensive areas of tumor necrosis that generate AAA
capable of optimally activate tumor-specific TH cells which in
turn activate CTL immune effectors. In both experimental
systems tumor rejection and persistent and long-lived TH cell
anti-tumor memory, responsible of defending the animals
from subsequent challenges with tumor cells, are achieved.
Based on these and other investigators’ results we propose that
AAA is a key element for triggering adaptive immune func-
tions resulting in subversion from a pro-tumor to an anti-
tumor microenvironment, tumor rejection and acquisition of
anti-tumor immune memory. Hypotheses of neuro-immune
networks involved in these approaches are discussed. These
considerations are important also for the comprehension of
how chemotherapy and/or radiation therapies may help to
block and/or to eradicate the tumor and for the construction
of suitable anti-tumor vaccine strategies.
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Introduction
A complex series of events are responsible for the generation
and spreading of cancer cells. These include intrinsic modifi-
cations of the tumor cells such as genetic mutations in proto-
oncogens and in tumor suppressor genes, which cumulatively
impact on the homeostasis of cell cycle and on the mechanisms
controlling apoptosis (Hanahan and Weinberg 2000), and the
efficiency of host response against tumor cells.Within the latter
category, certainly the immune response against the tumor play
an important role and components of both innate and adaptive
immunity have been shown to participate to this response
(Dunn et al. 2004). Nevertheless the fact that the tumor takes
off in cancer patients demonstrates that tumor may elude im-
mune defences (Rosenberg et al. 2004; Vesely et al. 2011).
Tumors are not simple entities. Tumors are tissues composed of
tumor cells, tumor stroma and often of a series of blood-derived
infiltrating leukocytes including cells of innate and adaptive
immunity (Jochems and Schlom 2011). Extensive studies have
demonstrated that tumor-infiltrating leukocytes, including neu-
trophils, eosinophils, mast cells, macrophages, (de Visser et al.
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2006; Sica et al. 2008) as well as T cells with CD4+/CD25+
phenotype and suppressive function on helper and effector T
cells, designated regulatory T cells (Tregs) (Nishikawa and
Sakaguchi 2010; Sakaguchi et al. 1995), can cooperate
in favouring, instead of antagonizing, tumor growth. These
findings have created the diffuse belief that a pro-tumor po-
larization of the innate and adaptive immunity is the cause for
tumor cells to survive, replicate and spread (Mantovani and
Sica 2010; Ruffell et al. 2010).
However, as seen from the side of the adaptive immune
response, the above events can be interpreted not as the cause
but simply as the consequence of the tumor strategy to pri-
marily counteract components of the acquired immunity, par-
ticularly T lymphocytes as these cells, including CD4+ T
helper (TH) and CD8+ cytolytic T lymphocytes (CTL), are
mostly involved in the anti-tumor response. In other words, if
the specific immune response against the tumor is put on
brake, then almost by default all other mechanisms of immu-
nity cannot react satisfactorily and the tumor takes off.
The purpose of this review is to re-establish the role of the
acquired immune response, that is specific antigen presentation,
stimulation of antigen-specific TH cells and generation of
antigen-specific effector T cells, as the leading mechanism of
defence against cancer. This principle is of paramount impor-
tance if strategies of either preventive or therapeutic vaccination
against tumors should be pursued, because adaptive immunity
with its capacity to produce specific responses, long lasting
protection and memory, is indeed the final goal of vaccination.
One of the most important steps in constructing a protective
adaptive immune response is the initial phase of antigen
recognition. Many elements, tumor-related and leukocyte-
related, may be evoked to justify a scarce initial activation of
tumor-specific T lymphocytes (see Fig. 1). Our focus will be
mainly on one of this element, the tumor antigen presentation
to CD4+ TH cells, because we believe this aspect is crucial in
orchestrating all the downstream events leading to an effective
anti-tumor adaptive immune response. Here we introduce the
concept of “Adequate Antigen Availability” (AAA), intended
not only as quantitative tumor antigen production but also as
optimal MHC class II (MHC-II)-dependent tumor antigen
presentation to efficiently trigger TH cells and, by this, the
downstream cascade of adaptive anti-tumor immunity to
counteract not only tumor onset but also established tumors.
This concept has important consequences not only for con-
ceiving suitable anti-tumor vaccines but also for understand-
ing how chemotherapy and/or radiation therapies may help to
block and/or to eradicate the tumor.
Inefficiency of adaptive immunity in tumor-bearing hosts
It has been widely shown that immune cells with specificity
for tumor-associated antigens can be found in cancer patients.
Based on the groundbreaking studies of Festeinstein and
colleagues (Hui et al. 1984), who demonstrated that CTL play
a major role in the elimination of tumor cells, most tumor
immunologists focussed initially their attention on the pres-
ence of CTL in tumor-bearing hosts. The concept of targeting
CTL responses has been based on the observation that most
cells express MHC-I, the cell surface molecule serving as
receptor for peptides derived from endogenously synthesized
proteins which are recognized by CTL. Indeed, tumor-specific
CTL can be isolated from tumor tissues, they can be amplified
in vitro and re-injected into hosts in which, at least in exper-
imental animal models, they can inhibit tumor take or even
cure established tumors (De Plaen et al. 1997). On this basis,
clinical trials using CTL-defined antigens as vaccines have
been performed. In most studies, however, CTL responses
were weak and unable to control tumor growth and metastasis
(Rosenberg et al. 2008). It was soon apparent that this event
was due not only to the frequent loss or reduced expression of
MHC-I molecules in tumor cells (Garcia-Lora et al. 2003;
Garrido et al. 2010; Kageshita et al. 1999) but also to the poor
tumor specific, MHC class II (MHC-II)-restricted T cell help
generated in tumor-bearing patients (Huang et al. 1994;
Ossendorp et al. 1998), since TH cells are fundamental for
optimal induction of both humoral and cellular effector mech-
anisms (Pardoll and Topalian 1998) and particularly for CTL
maturation, clonal expansions and acquisition of cytolytic
function (Hung et al. 1998).
TH cell triggering requires recognition of antigenic peptides
presented by MHC-II molecule expressed on professional an-
tigen presenting cells (APC) including dendritic cells, macro-
phages and B cells (Germain andMargulies 1993). Eluding the
crucial phase of MHC-II-dependent tumor antigen presentation
to and/or activation of TH cells would thus be an effective
strategy to block the onset of the adaptive anti-tumor immune
response.
Adequate antigen availability: a key element
for generating an efficient anti-tumor immunity
In order to obtain a suitable anti-tumor TH cell response, an
adequate antigen availability (AAA), must be provided. The
nature of the antigen presenting cells is not specified here
intentionally, because this role could be played, at least in
part, by the tumor cells themselves. We will consider recent
results of our group and of other investigators to put forward
the concept that AAA is indeed a key element for generating
the cascade of immune effector functions and polarizing
signals that result in tumor rejection and acquisition of
anti-tumor immune memory.
Almost five decades ago Mitchison demonstrated the
importance of antigen dose in triggering an adaptive im-
mune response (Makela and Mitchison 1965; Mitchison
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1964) by showing that low amounts of protein antigen
would never trigger an immune response and might even
be tolerogenic. The original Mitchison’s “low antigen dose-
low immune response” paradigm was recently adapted and
up-dated by Zinkernagel and coll. who elaborated the con-
cept that for tumor antigens not only the quantity but also
the “geographic availability” is crucial to instruct the adap-
tive immune system (Zinkernagel et al. 1997). Should cells
of adaptive immunity not have the chance to encounter the
tumor cells because the tumor remains localized at sites out
of contact with immune cells, then the tumor will be
neglected, ignored by the immune system.
Preventive anti-tumor vaccination and adequate antigen
availability: the strategy of CIITA-induced MHC class II
expression in tumor cells
In recent years, many attempts have been made to construct
preventive anti-tumor vaccines by using as a primary source
of antigen whole tumor cells treated by different procedures
to make them more immunogenic. Irradiated or genetically
modified tumor cells have been used even in clinical trials
(Dranoff 2004). These approaches, however, were mostly
focussed on providing host’s APC with tumor antigens or to
generate within the tissue injected with tumor cells a suit-
able milieu for optimal APC (mostly dendritic cells (DC))
uptake and presentation of tumor antigens via the APC
MHC class II molecules.
As a different approach to obtain AAA for triggering the
adaptive anti-tumor immune response, a vaccination strategy
with tumor cells transduced with the AIR-1-encoded MHC-II
transactivator CIITA, discovered in our laboratory (Accolla et
al. 1986; Accolla et al. 1985b; Accolla et al. 1985c; Steimle et
al. 1993) has been explored. The rationale underlying this
approach was based on the evidence that, beside controlling
MHC-II gene expression, CIITA may positively act on other
crucial steps of the antigen processing and presentation mech-
anism, such as MHC-II transport in endocytic compartments
via its function on the upregulation of Invariant chain expres-
sion (Accolla et al. 1985a; Meazza et al. 2003) and on antigen
loading on MHC-II molecules via its upregulation on the
MHC-II accessory molecule DM (Harton and Ting 2000).
Thus the idea was that CIITA-transfected tumor cells may
act as “surrogate APC” via MHC-II-restricted tumor-
associated antigen presentation to tumor-specific TH cells
for their optimal triggering. This in turn would facilitate
priming and activation of tumor-specific CTL, hopefully
resulting in tumor cell killing (see Fig. 2).
Crucial to this approach were the assumptions, verified
by previous elegant studies, that endogenous proteins, as
most tumor antigens are, could access the MHC class II
pathway of antigen presentation (Rudensky et al. 1991;
Schimd et al. 2007) and that peptides of these proteins could
be recognized and serve as immunogen for TH cell trigger-
ing (Chicz et al. 1993; Jaraquemada et al. 1990).
We could demonstrate that efficient rejection of CIITA-
transduced tumor cells of distinct histological origin can be
achieved in high percentage of injected immunocompetent
syngeneic mice (Frangione et al. 2010; Meazza et al. 2003;
Mortara et al. 2006). Furthermore, it was shown that CIITA-
tumor vaccinated mice develop an anamnestic response
Fig. 1 Elements that can
contribute to the inefficient
adaptive immune response
against cancer. T lymphocytes
(including TH and CTL) are
considered as the major target
subpopulation whose altered/
limited function can lead to
inefficient anti-tumor adaptive
immunity. Weak activation of
tumor-specific T cells can result
from either tumor-related prop-
erties and/or products (1, 2, 3)
or leukocytes-related character-
istics (4, 5, 6, 7). Abbreviation
used: T-regs, regulatory T cells;
MDSC, myeloid-derived sup-
pressor cells; DC, dendritic
cells; TH2, T helper 2-polarized
cells; M2, macrophages polar-
ized toward an M2 phenotype
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upon challenge with the parental tumor leading to a very
efficient rejection of the parental tumor (Frangione et al.
2010; Meazza et al. 2003; Mortara et al. 2006). That CIITA-
dependent MHC class II expression in tumor cells was
instrumental to trigger the anamnestic protective immune
response against the parental tumor, was also demonstrated
by vaccination experiments with non replicating CIITA-
transfected tumor cells (Mortara et al. 2009). Rejection
and/or reduced tumor growth were mediated by tumor spe-
cific CD4+ TH and CD8+ CTL (Frangione et al. 2010;
Meazza et al. 2003; Mortara et al. 2006; Mortara et al.
2009). Importantly, we could demonstrate that tumor-
specific, primed TH cells were long-living memory cells
and they could adoptively transfer resistance to tumor take
and/or tumor growth even after many months from original
stimulation (Frangione et al. 2010), indicating the stabiliza-
tion of a protective phenotype of effector cells over time.
Critical insight on the mechanisms triggered by CIITA-
transfected tumor cells and their possible role as surrogate
APCs was provided by the comparative analysis of the
tumor microenvironment and of tumor draining lymph
nodes in mice injected with parental or with CIITA-
transfected tumor cells (Mortara et al. 2006). Tumors de-
rived from parental cells showed little infiltrate, represented
mainly by macrophages and neutrophils, very few CD4+ T
cells and absence of DC and CD8+ T cells. In contrast the
site of CIITA-transfected tumor cell injection was rapidly
infiltrated by CD4+ T cells. This was followed 2 to 4 days
later by the appearance of DC and CD8+ T cells and by the
generation of extensive areas of tumor cell necrosis. Thus
CD4+ T cells colonized CIITA-tumor tissue before CD8+ T
cells and DC. This finding, along with the capacity of
CIITA-expressing tumor cells to process and present anti-
genic peptides to CD4+ T cells in vitro (Mortara et al. 2006;
Sartoris et al. 1998), supports the hypothesis that much of
the tumor-specific TH cell triggering and/or restimulation
takes place in the tumor tissue itself and is directly mediated
by tumor cell-derived MHC class II molecules.
Interestingly, CIITA-tumor vaccinated mice displayed a po-
larized CD4+ TH1 cell phenotype in tumor-draining lymph
nodes, as compared to a TH2-like cell phenotype found in
parental tumor-bearing mice. Moreover, the fact that CIITA-
transfected tumor cells could trigger a potent anamnestic and
persistent anti-tumor Tcell response without an apparent sequel
of autoimmunity, suggests that most of the anti-tumor response
was directed against tumor-and not self-derived antigens.
The success of this strategy underscores the importance
of an adequate MHC-II-restricted antigen presentation, sug-
gests that most tumor cells produce sufficient amounts of
tumor antigens and renders unnecessary to know a priori the
nature, the identity and the immunogenic hierarchy of the
tumor-associated antigen(s). In conclusion, inducing appro-
priate MHC-II expression in tumor cells may be a way to
satisfy the requirement of AAA.
Therapeutic anti-tumor vaccination and adequate antigen
availability: the strategy of L19-TNFα conjugate treatment
of established tumors
Immune-based tumor therapy approaches are presently an
intensive area of investigation for their potential and
Fig. 2 Amodel to explain how CIITA-inducedMHC class II expression
in tumor cells may render these cells “surrogate”APC of their own tumor-
associated antigens for MHC-II-restricted TH cells. a professional APC,
such as dendritic cells (DC), macrophages (Mϕ) and B cells, present in an
MHC-II ( )-restricted fashion, processed antigens to CD4+ TH cells.
Initial priming of TH cells is mainly due to DC-mediated antigen presen-
tation. TH activation is required to induce optimal activation and effector
function of CD8+ naïve CTL that, upon recognition of antigen presented
by MHC class I molecules ( ) on target cells may exert their cytolytic
activity. b transfection of CIITA into tumor cells renders themMHC class
II-positive and thus potentially suitable to act as surrogate APC for tumor-
specific, MHC-II-restricted TH cells. In turn, activated TH cells induce
optimal priming and activation of tumor-specific CTL precursors that will
kill the same tumor cells in an MHC-I-restricted fashion
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promising application to cancer patients. We have per-
formed experiments of tumor therapy in animal models by
using mouse TNFα (mTNFα) covalently bound to a Fv
antibody (L19) specific for the beta form of Fibronectin,
selectively expressed in tumor neovasculature (Borsi et al.
2003). Injection of L19mTNFα conjugate induces a dramat-
ic necrosis of established tumors as it allows concentrating
therapeutically active doses of TNFα at the tumor site.
When combined with the cytostatic drug melphalan, this
treatment dramatically potentiated the effect of melphalan
at the tumor site. Moreover L19mTNFα increases intravasal
coagulation and trombosis around the tumor further favor-
ing tumor necrosis. The effect of TNFα on vascular perme-
ability and on upregulation of adhesion molecules triggers
the inflammatory response at the tumor site by facilitating
leukocytes extravasation and dendritic cell migration through
lymphatic vessels (see Fig. 3).
Two crucial observations were made in this approach
which underline the importance of the adaptive immune
response against the tumor and are relevant for the AAA
hypothesis. First, a high rate of complete and long-lasting
tumor eradication in distinct tumor models, without any
apparent adverse side effects and with no recurrence, was
observed. Second, tumor-bearing immunodeficient SCID
mice were partially resistant to the L19mTNFα treatment
even when combined with melphalan (Balza et al. 2006).
This prompted us to analyze whether the cured mice devel-
oped a tumor-specific immunity. Indeed, all cured mice
were resistant to tumor challenge; the tumor rejection was
mediated by CTL and, particularly, by long-living, tumor
specific TH cells, whereas B cells and NK cells did not play
any significant role (Balza et al. 2006). TH cells were
crucial for the establishment of what we defined as “therapy
induced anti-tumor vaccination” because naive mice deplet-
ed of TH cells were unable to reject primary tumors after
L19mTNFα/melphalan treatment (Mortara et al. 2007).
Moreover, TH cells derived from cured animals treated with
L19mTNFα/melphalan, while fully competent in generating
tumor rejection when adoptively transferred together with
tumor cells in naive mice, were incapable of inducing tumor
rejection in CD8-depleted naïve animals, strongly suggest-
ing that a major protective role of primed anti-tumor CD4+
T cells lies in triggering CD8+ naive T cells to become
functionally mature antitumor CTL effectors (Mortara et
al. 2007). Altogether these findings indicate that the
L19mTNFα/melphalan treatment was crucial in generating
tumor AAA to efficiently trigger, in an MHC-II-restricted
fashion, tumor specific TH cells that subsequently triggered
naïve CTL precursors and sustained their cytolytic anti-
tumor effector function (see Figs. 3 and 4).
Immunohistochemical characterization of the tumor tis-
sue early after treatment revealed the presence of areas of
necrosis with infiltration of granulocytes and macrophages.
One week after L19mTNFα/melphalan treatment a remark-
able increase in the number of CD4+ and CD8+ T cells
infiltrating the tumor was observed as compared to tumors
from untreated animals. This was accompanied by a drastic
increase in granulocyte infiltration and by the enlargement
of areas of tumor necrosis (Mortara et al. 2007). Thus, the
tumor necrosis induced by L19mTNFα/melphalan and the
earlier infiltration of granulocytes contributing to tumor cell
killing could be the important element to generate Adequate
Antigen Availability for fuelling professional APC. These
APC could then stimulate specific antitumor CD4+ TH cells
and CD8+ effector CTL, leading to the complete rejection of
the tumor and to the establishment of a critical reservoir of
memory effector cells responsible for the accelerated rejec-
tion of the tumor upon challenge. Interestingly, more refined
phenotypic and functional characterization of the CD4+ T
cells involved in the priming of the anti-tumor immune
response following therapeutic treatment revealed that,
while untreated tumor-bearing mice had in their spleen and
tumor-draining lymph nodes IL-4-secreting TH2-type cells,
treated mice displayed a mixed TH1- and TH2-type of
response with a large percentage of cells secreting IFNγ
(Balza et al. 2010; Mortara et al. 2007). Thus, likely the
preventive vaccination approach with CIITA-expressing tu-
mor cells, a rapid appearance and conversion toward a TH1
immune phenotype was associated to the protective anti-
tumor immune response generated by the treatment with
L19mTNFα and melphalan. This preliminary in vivo exper-
imental investigation has paved the way to initiate clinical
trials with L19mTNFα and melphalan in patients with se-
lected tumors (Papadia et al. 2012)
Neuro-immune networks and their potential exploitation
against the tumors
A relevant observation of our studies was that both in the
therapy-induced vaccination generated by treating tumor-
bearing hosts with TNFα and melphalan and in the preven-
tive CIITA-tumor vaccination approach a strong reduction
of CD4+CD25+ regulatory T cells (Tregs) in tumor-
draining lymphonodes was observed (Mortara et al. 2007;
Mortara et al. 2009). This suggests that the anti-tumor
polarization generated by the two treatments counteracted
or prevented the increase and/or the recruitment of Tregs in
tumor-draining tissues. Therefore modulating the number
and/or the function of Tregs may act as an important “adju-
vant” to synergize the protective effect of our vaccination
strategies. Within this frame, neuro-immune interactions
may play an important role. Indeed, it has been recently
shown that Tregs express receptors for neurotransmitters and
particularly dopamine (DA) receptors (DARs) (Cosentino et
al. 2007). Moreover DA, together with norepinephrine (NE)
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and epinephrine (E), is also produced and utilized by
immune cells themselves (Cosentino et al. 2003). In human
lymphocytes the synthesis of DA, NE and E is induced
upon activation through tyrosine hydroxylase (the first and
rate-limiting enzyme in their synthesis), resulting in intra-
cellular accumulation, release and subsequent action on
lymphocytes themselves and/or neighbouring cells. It has
been shown that Tregs constitutively express tyrosine hy-
droxylase and DARs and contain high amounts of DA, NE
and E, which subserve an autocrine/paracrine loop involv-
ing DAergic D1-like (D5) receptors and resulting in down
regulation of Treg inhibitory functions (Cosentino et al.
2007). The existence in lymphocytes of an endogenous
DAergic/adrenergic system may thus represent a novel
and so far unexploited target for the selective modulation
of the immune response, particularly in cancer-bearing
hosts undergoing immunotherapeutic approaches as the
one described in the present paper. Indeed, while functional
suppression of Treg is mediated by D1-like D5 receptors
(Cosentino et al. 2007), physiological concentrations of DA
can even drive resting human T cells into functional acti-
vation through D2, D3, and D1/D5 DA receptors (Besser et
al. 2005). The use of selective D1/D5 agonists in vivo
might thus result in functional activation of effector T
lymphocytes both directly as well as through the functional
suppression of Treg function. Interestingly, it ha been re-
cently reported that beta2 adrenergic receptor (beta2-AR)
expression is reduced in astrocytes in pathological states as
Multiple Sclerosis (MS) (De Keyser et al. 2010).
Astrocytes may express CIITA and thus MHC-II molecules
and they may act as surrogate APC for autoantigen in
autoimmune diseases like MS (Soos et al. 1998). Since
stimulation of beta2-AR increases cAMP, leading to activa-
tion of protein kinase A (PKA) a suppressor of CIITA
expression, beta2-AR deficiency in astrocytes of MS may
result, in turn, in the reduction of the suppressive action of
PKA on CIITA, potentially contributing to the perpetuation
of the disease. Thus it would be important to investigate
whether certain tumor cell types, susceptible to express
MHC class II molecules, may express functional beta2-
AR, because beta2-AR antagonists can be used as a poten-
tial additional tool to maintain MHC-II expression and
surrogate tumor antigen presenting function in cancer
patients.
Fig. 3 Major biological effects of TNFα relevant for the triggering of
the adaptive immune response against the tumor: a possible scenario.
TNFα, targeted to tumor neovessels by covalent binding to a Fv
antibody (L19) specific for the beta form of Fibronectin (FN-B),
selectively expressed in tumor neovasculature, has direct access to
the tumor mass in which may induce direct killing and necrosis (1).
Increased concentration of TNFα favors intravasal coagulation and
trombosis (2) with additional necrosis of tumor tissue (3). TNFα
potently increases vascular permeability (4) with consequent
extravasation of blood-derived leukocyte and initiation of an inflam-
matory reaction which recruits additional lymphocytes (L), dendritic
cells (DC) and granulocytes (Gr) in the tumor area. DC capture necrot-
ic cell debris rich in tumor-associated antigens and, via the upregula-
tion of adhesion molecules (5) also contributed by TNFα, migrate to
the tumor-draining lymphonodes where tumor-specific lymphocytes
can be triggered and further sent via circulation to the tumor site where
they can act as immune effectors against the tumor
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Radiotherapy and chemotherapy as procedures
to potentially offer AAA
The experimental evidences gathered from our approaches
of either preventive or therapy-induced anti-tumor vaccina-
tion clearly demonstrate that a subversion toward an anti-
tumor microenvironment can be generated by promoting
AAA not only before the tumor onset but also after cancer
has developed (see Fig. 4).
In consideration of the above findings and taking into
account that an AAA can be obtained in different ways,
a large series of previously published studies on the
appearance of an anti-tumor immune response following
conventional anti-tumor therapy, may be re-interpreted
also as a way to offer AAA to the adaptive immune
system.
For example, tumor site-specific radiation therapy (RT),
given alone (Takeshima et al. 2010) or in combination with
immunostimulatory cytokines (IL-2 and TNFα) (Lee et al.
2000; Yamini et al. 2007) enhances its efficacy by generat-
ing anti-tumor specific CTL responses. RT can also increase
CTL stimulation by up-regulating MHC class I expression
in tumor cells (Lugade et al. 2005; Reits et al. 2006) and,
more interestingly, by positively influencing antigen pro-
cessing and presentation by dendritic cells (Liao et al.
2004). Similar findings have been reported also after treat-
ment of localized tumors with thermoablative techniques
(Haen et al. 2011)
Chemotherapy can also increase the immunogenicity of
tumor cells which are recognized by immune effectors
(Zitvogel et al. 2011). Central to this role of RT and
Chemotherapy is the concept of immunogenic cell death
that, induced by the therapeutical agent, finally ends up in
the triggering of an adaptive immune response (Lake and
Robinson 2005), a concept that can be easily accommodated
within the hypothesis of AAA ( see Fig. 4).
Fig. 4 Adequate Antigen Availability (AAA) as a key parameter for
an effective anti-tumor adaptive immune response. AAA as defined in
the text may result from either surrogate antigen presenting activity by
tumor cells expressing CIITA-dependent MHC class II (MHC-II) mol-
ecules or by increasing the amount of tumor antigen availability for
classical antigen-presenting cells (APC) via therapeutical approaches
resulting in immunogenic cell death, such as radiotherapy (RT), che-
motherapy, and biotherapy with, for example, L19-TNFα and melpha-
lan (L19-TNFα + Melphalan). AAA generated by the two approaches
is instrumental for the optimal triggering of anti-tumor CD4+ T helper
cells (TH). These MHC-II-restricted anti-tumor TH cells have a dual
action in the process of immune-mediated tumor rejection: a they are
required for the activation, proliferation and cytolytic activity of CD8+
anti-tumor cytotoxic T lymphocytes (CTL); b they are major players in
the subversion of the tumor microenvironment toward an anti-tumor
milieu by polarizing, for example, the lymphocyte infiltrate toward a
mixed TH1/TH2 or exclusive TH1 population with an increased fre-
quency of IFNγ secreting cells, by favouring the recruitment of in-
flammatory cells such as polymorphonucleates (PMN), by inhibiting
the function and/or the recruitment of leukocytes with suppressive
action on TH cells and on tumor-specific CTL such as regulatory T
cells (Tregs)
34 J Neuroimmune Pharmacol (2013) 8:28–36
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This will possibly help to better understand the initial
phases of the immune response against tumors and offer
potential new strategies to prevent and fight cancer.
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